Shane Prejean, MD
Advanced Heart Failure and Transplant Cardiology · Houma, LANPI 1609141985
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (59.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Edwards Lifesciences at 40.5% of the total. Reporting peaked in 2020 at $63,872 and has fallen 55.8% since, to $28,227 in 2025.
Across 243 payments — averaging $420.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$41K
- Novo Nordisk$23K
- Medtronic$16K
- Boston Scientific$14K
- Abbott$5K
- Angiodynamics, Inc.$674
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$23,15623%
- Grants$60,50059%
- Travel & lodging$6,9127%
- Food & beverage$11,64511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 29 | $41,359 |
| Novo Nordisk | 13 | $22,852 |
| Medtronic(2 entities) | 71 | $16,469 |
| Boston Scientific | 12 | $14,430 |
| Abbott | 57 | $4,514 |
| Angiodynamics, Inc. | 4 | $674 |
| W. L. Gore & Associates, Inc. | 2 | $343 |
| E.r. Squibb & Sons, L.L.C. | 8 | $226 |
| Kestra Medical Technology Services, Inc. | 11 | $196 |
| Abiomed | 5 | $162 |
| Shockwave Medical, Inc | 1 | $150 |
| Imperative Care, Inc | 2 | $139 |
| AstraZeneca | 1 | $125 |
| Pfizer | 5 | $92 |
| Philips North America LLC | 2 | $91 |
| Inari Medical, Inc. | 4 | $83 |
| Amgen | 4 | $78 |
| Boehringer Ingelheim | 3 | $44 |
| Livanova USA, Inc. | 1 | $28 |
| Mannkind Corporation | 1 | $25 |
| Stryker | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Merck | 1 | $16 |
| Terumo Medical Corporation | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$22,746
- GENERAL - STRUCTURAL HEART$12,624
- COREVALVE EVOLUT R$2,361
- CoreValve Evolut$1,962
- Watchman$1,500
- EVOQUE$1,403
- TRICLIP$1,380
- AMPLATZER Occluders$719
- AlphaVac$448
- Avalus$428
- MitraClip$369
- GORE CARDIOFORM Septal Occluder$202
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$150
- PASCAL$150
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$148
- CARDIOFORM Septal Occluder$141
- GENERAL VASCULAR ACCESS$130
- Auryon Laser System 100-120 Vac$127
- FARXIGA$125
- CAMZYOS$125
How this compares
Too few advanced heart failure and transplant cardiology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 17 | $582,830 |
| EliquisApixaban | 499 | $473,045 |
| JardianceEmpagliflozin | 223 | $213,389 |
| CamzyosMavacamten | 23 | $183,559 |
| EntrestoSacubitril/Valsartan | 138 | $162,589 |
| OzempicSemaglutide | 138 | $161,905 |
| Repatha SureclickEvolocumab | 120 | $102,818 |
| XareltoRivaroxaban | 63 | $71,570 |
| Repatha PushtronexEvolocumab | 48 | $45,725 |
| MounjaroTirzepatide | 25 | $30,895 |
| BrilintaTicagrelor | 33 | $29,664 |
| WegovySemaglutide | 18 | $23,545 |
| FarxigaDapagliflozin Propanediol | 25 | $17,079 |
| VeltassaPatiromer Calcium Sorbitex | 15 | $16,067 |
| Rosuvastatin Calcium | 1,220 | $14,361 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $92 | $1,055,875516 claims |
| Boehringer IngelheimJardiance | $44 | $213,389223 claims |
| Novo NordiskOzempic, Wegovy | $22,852 | $185,449156 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $226 | $183,55923 claims |
| Johnson & JohnsonXarelto | $14 | $71,57063 claims |
| AstraZenecaBrilinta, Farxiga | $125 | $46,74358 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Houma
- Peter FailHouma$206K
- Clement EiswirthNew Orleans$277K
- David MollBaton Rouge$55K
- Senthil AnandNew Orleans$51K
- Siby AyallooreOpelousas$45K
- Hector VenturaNew Orleans$39K
- Phillip SmithBaton Rouge$34K
- Sapna DesaiNew Orleans$30K
- John LawrenceLafayette$17K
- Mohammad El BabaShreveport$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.